Xtx Topco LTD Alnylam Pharmaceuticals, Inc. Transaction History

Xtx Topco LTD

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 12, 2024	SELL	$143.31 - $247.0 $476,505 - $821,275	-3,325 Reduced 69.2%	1,480 $359,000
Q1 2024 May 13, 2024	BUY	$146.51 - $198.2 $703,980 - $952,351	4,805 New	4,805 $718,000
Q3 2023 Nov 13, 2023	BUY	$170.77 - $211.65 $739,775 - $916,867	4,332 Added 96.18%	8,836 $1.56 Million
Q2 2023 Aug 14, 2023	BUY	$185.01 - $212.05 $833,285 - $955,073	4,504 New	4,504 $855,000
Q3 2022 Nov 14, 2022	BUY	$138.54 - $232.0 $538,089 - $901,088	3,884 New	3,884 $777,000
Q2 2022 Aug 15, 2022	SELL	$120.42 - $169.29 $180,268 - $253,427	-1,497 Closed	0 $0
Q1 2022 May 13, 2022	BUY	$127.18 - $173.91 $190,388 - $260,343	1,497 New	1,497 $244,000

645

109M

1.28M

1.22M

Ticker ALNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 123,028,000
Market Cap $30.3B
Description
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...

Get notified when there are updates to the investment portfolio of Xtx Topco LTD, based on Form 13F filings with the SEC.

Stay updated on Xtx Topco LTD with notifications on news.